Sylvia Villeneuve

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/8300340/publications.pdf

Version: 2024-02-01

59 papers	2,597 citations	218381 26 h-index	205818 48 g-index
76 all docs	76 docs citations	76 times ranked	4195 citing authors

#	Article	IF	Citations
1	Trait Mindfulness Is Associated With Less Amyloid, Tau, and Cognitive Decline in Individuals at Risk for Alzheimerâ€™s Disease. Biological Psychiatry Global Open Science, 2023, 3, 130-138.	1.0	6
2	Apolipoprotein B is a novel marker for early tau pathology in Alzheimer's disease. Alzheimer's and Dementia, 2022, 18, 875-887.	0.4	22
3	Plasma pâ€tau231, pâ€tau181, <scp>PET</scp> Biomarkers, and Cognitive Change in Older Adults. Annals of Neurology, 2022, 91, 548-560.	2.8	42
4	Prevalence Estimates of Amyloid Abnormality Across the Alzheimer Disease Clinical Spectrum. JAMA Neurology, 2022, 79, 228.	4.5	97
5	Regional brain atrophy and cognitive decline depend on definition of subjective cognitive decline. NeuroImage: Clinical, 2022, 33, 102923.	1.4	16
6	Tau PET Imaging in Neurodegenerative Disorders. Journal of Nuclear Medicine, 2022, 63, 20S-26S.	2.8	26
7	Amyloid and Tau Pathology Associations With Personality Traits, Neuropsychiatric Symptoms, and Cognitive Lifestyle in the Preclinical Phases of Sporadic and Autosomal Dominant Alzheimerâ€™s Disease. Biological Psychiatry, 2021, 89, 776-785.	0.7	30
8	The impact of demographic, clinical, genetic, and imaging variables on tau PET status. European Journal of Nuclear Medicine and Molecular Imaging, 2021, 48, 2245-2258.	3.3	27
9	Open science datasets from PREVENT-AD, a longitudinal cohort of pre-symptomatic Alzheimerâ€™s disease. NeuroImage: Clinical, 2021, 31, 102733.	1.4	42
10	Vascular risk factors are associated with a decline in resting-state functional connectivity in cognitively unimpaired individuals at risk for Alzheimer's disease. NeuroImage, 2021, 231, 117832.	2.1	10
11	Bundle-specific associations between white matter microstructure and AÎ² and tau pathology in preclinical Alzheimerâ€™s disease. ELife, 2021, 10, .	2.8	26
12	Accelerated functional brain aging in pre-clinical familial Alzheimerâ€™s disease. Nature Communications, 2021, 12, 5346.	5.8	43
13	Association of a Total Cholesterol Polygenic Score with Cholesterol Levels and Pathological Biomarkers across the Alzheimerâ€™s Disease Spectrum. Genes, 2021, 12, 1805.	1.0	3
14	Association of education with AÎ² burden in preclinical familial and sporadic Alzheimer disease. Neurology, 2020, 95, e1554-e1564.	1.5	12
15	Association of vascular brain injury, neurodegeneration, amyloid, and cognitive trajectory. Neurology, 2020, 95, e2622-e2634.	1.5	27
16	Repetitive negative thinking is associated with amyloid, tau, and cognitive decline. Alzheimer's and Dementia, 2020, 16, 1054-1064.	0.4	52
17	Intermediate flortaucipir uptake is associated with AÎ²-PET and CSF tau in asymptomatic adults. Neurology, 2020, 94, e1190-e1200.	1.5	30
18	Morphometric network differences in ageing versus Alzheimerâ€™s disease dementia. Brain, 2020, 143, 635-649.	3.7	37

#	Article	IF	Citations
19	Characterization of Alzheimer Disease Biomarker Discrepancies Using Cerebrospinal Fluid Phosphorylated Tau and AV1451 Positron Emission Tomography. JAMA Neurology, 2020, 77, 508.	4.5	79
20	Association of Vascular Risk Factors With Î²-Amyloid Peptide and Tau Burdens in Cognitively Unimpaired Individuals and Its Interaction With Vascular Medication Use. JAMA Network Open, 2020, 3, e1920780.	2.8	36
21	Lifespan Cognitive Reserveâ€"A Secret to Coping With Neurodegenerative Pathology. JAMA Neurology, 2019, 76, 1145.	4.5	5
22	AD molecular: PET amyloid imaging across the Alzheimer's disease spectrum: From disease mechanisms to prevention. Progress in Molecular Biology and Translational Science, 2019, 165, 63-106.	0.9	10
23	Vascular Burden Score Impacts Cognition Independent of Amyloid PET and MRI Measures of Alzheimerâ€™s Disease and Vascular Brain Injury. Journal of Alzheimer's Disease, 2019, 68, 187-196.	1.2	25
24	ICâ€Pâ€091: CEREBROSPINAL FLUID AND PET MEASURES OF TAU PATHOLOGY INDICATE DIFFERENT STATE OF AD PATHOPHYSIOLOGICAL PROGRESSION. Alzheimer's and Dementia, 2019, 15, P80.	0.4	0
25	Dataâ€driven approaches for tauâ€PET imaging biomarkers in Alzheimer's disease. Human Brain Mapping, 2019, 40, 638-651.	1.9	27
26	Proximity to Parental Symptom Onset and Amyloid-Î² Burden in Sporadic Alzheimer Disease. JAMA Neurology, 2018, 75, 608.	4.5	19
27	Brain properties predict proximity to symptom onset in sporadic Alzheimerâ€™s disease. Brain, 2018, 141, 1871-1883.	3.7	43
28	Subjective Cognitive Decline Is Associated With Altered Default Mode Network Connectivity in Individuals With a Family History of Alzheimerâ€™s Disease. Biological Psychiatry: Cognitive Neuroscience and Neuroimaging, 2018, 3, 463-472.	1.1	41
29	O1â€03â€06: EARLY INCREASE IN TAUâ€PET SIGNAL IS ASSOCIATED WITH AÎ² BURDEN, CSF Pâ€TAU LEVELS AND COGNITION IN COGNITIVELY NORMAL LATEâ€MIDDLEâ€AGED ADULTS. Alzheimer's and Dementia, 2018, 14, P222.	0.4	1
30	Regional correlations between [11 C]PIB PET and post-mortem burden of amyloid-beta pathology in a diverse neuropathological cohort. NeuroImage: Clinical, 2017, 13, 130-137.	1.4	50
31	Multimodal characterization of older APOE2 carriers reveals selective reduction of amyloid load. Neurology, 2017, 88, 569-576.	1.5	50
32	White Matter Structure in Older Adults Moderates the Benefit of Sleep Spindles on Motor Memory Consolidation. Journal of Neuroscience, 2017, 37, 11675-11687.	1.7	42
33	Highly efficient solid phase supported radiosynthesis of <scp>[¹¹C]PiB</scp> using <scp>tC18</scp> cartridge as a â€œ3â€in‐â€1â€•production entity. Journal of Labelled Compounds and Radiopharmaceuticals, 2017, 60, 632-638.	0.5	12
34	[P4â€“525]: DATAâ€DRIVEN TAUâ€PET COVARIANCE NETWORKS ENHANCE PREDICTION OF RETROSPECTIVE COGNITIVE CHANGE IN ALZHEIMER's DISEASE. Alzheimer's and Dementia, 2017, 13, P1548.	0.4	1
35	Cause of Suspected Nonâ€“Alzheimer Disease Pathophysiology. JAMA Neurology, 2016, 73, 1177.	4.5	5
36	Î²-amyloid, hippocampal atrophy and their relation to longitudinal brain change in cognitively normal individuals. Neurobiology of Aging, 2016, 40, 173-180.	1.5	27

#	Article	IF	Citations
37	IC-01-01: Are low levels of PiB-PET signal clinically significant?. , 2015, 11, P1-P1.		0
38	P3-145: Are low levels of PiB-PET signal clinically significant?. , 2015, 11, P681-P682.		0
39	Are AD-Typical Regions the Convergence Point of Multiple Pathologies?. Frontiers in Aging Neuroscience, 2015, 7, 42.	1.7	16
40	Influence of Abdominal Obesity on the Lipid-Lipoprotein Profile in Apoprotein E2/4 Carriers: The Effect of an Apparent Duality. Journal of Lipids, 2015, 2015, 1-10.	1.9	10
41	Existing Pittsburgh Compound-B positron emission tomography thresholds are too high: statistical and pathological evaluation. Brain, 2015, 138, 2020-2033.	3.7	319
42	IMAGING VASCULAR DISEASE AND AMYLOID IN THE AGING BRAIN: IMPLICATIONS FOR TREATMENT. journal of prevention of Alzheimer's disease, The, 2015, 2, 1-7.	1.5	25
43	Cortical thickness mediates the effect of Î²-amyloid on episodic memory. Neurology, 2014, 82, 761-767.	1.5	39
44	The potential applications of Apolipoprotein E in personalized medicine. Frontiers in Aging Neuroscience, 2014, 6, 154.	1.7	40
45	Associations Between Serum Cholesterol Levels and Cerebral Amyloidosis. JAMA Neurology, 2014, 71, 195.	4.5	201
46	Vascular risk and AÎ² interact to reduce cortical thickness in AD vulnerable brain regions. Neurology, 2014, 83, 40-47.	1.5	83
47	Gene-Environment Interactions: Lifetime Cognitive Activity, APOE Genotype, and Beta-Amyloid Burden. Journal of Neuroscience, 2014, 34, 8612-8617.	1.7	107
48	Neuroprotective pathways: lifestyle activity, brain pathology, and cognition in cognitively normal older adults. Neurobiology of Aging, 2014, 35, 1873-1882.	1.5	102
49	O3-10-02: LIFETIME COGNITIVE ACTIVITY, APOLIPOPROTEIN E GENOTYPE, AND BRAIN BETA-AMYLOID. , 2014, 10, P228-P228.		1
50	Associations Between Alzheimer Disease Biomarkers, Neurodegeneration, and Cognition in Cognitively Normal Older People. JAMA Neurology, 2013, 70, 1512-9.	4.5	139
51	Influence of Obstructive Sleep Apnea on Cognitive Impairment in Patients With COPD: Response. Chest, 2013, 143, 1512-1513.	0.4	2
52	Predicting Progression to Dementia in Elderly Subjects with Mild Cognitive Impairment Using Both Cognitive and Neuroimaging Predictors. Journal of Alzheimer's Disease, 2013, 38, 307-318.	1.2	69
53	Associations between White Matter Hyperintensities and Î² Amyloid on Integrity of Projection, Association, and Limbic Fiber Tracts Measured with Diffusion Tensor MRI. PLoS ONE, 2013, 8, e65175.	1.1	77
54	Mild Cognitive Impairment in Moderate to Severe COPD. Chest, 2012, 142, 1516-1523.	0.4	147

#	Article	IF	Citations
55	The nature of memory failure in mild cognitive impairment: examining association with neurobiological markers and effect of progression. Neurobiology of Aging, 2012, 33, 1967-1978.	1.5	16
56	The effect of semantic orientation at encoding on free-recall performance in amnestic mild cognitive impairment and probable Alzheimer's disease. Journal of Clinical and Experimental Neuropsychology, 2011, 33, 631-638.	0.8	23
57	The nature of episodic memory deficits in MCI with and without vascular burden. Neuropsychologia, 2011, 49, 3027-3035.	0.7	37
58	Validity of the Mattis Dementia Rating Scale to Detect Mild Cognitive Impairment in Parkinsonâ€™s Disease and REM Sleep Behavior Disorder. Dementia and Geriatric Cognitive Disorders, 2011, 31, 210-217.	0.7	45
59	Impact of Vascular Risk Factors and Diseases on Cognition in Persons with Mild Cognitive Impairment. Dementia and Geriatric Cognitive Disorders, 2009, 27, 375-381.	0.7	52